31 results about "Pluronic F68" patented technology

The invention relates to an NT-proBNP fluorescence immunoassay reagent and a preparing method thereof, which belong to the technical field of medical detection. The NT-proBNP fluorescence immunoassay reagent comprises an NT-proBNIP antibody for marking, a goat anti-chicken IgY antibody for marking, an NT-proBNP2 antibody for coating, a chicken IgY antibody for coating, a particle resuspension and a sample pad conditioning fluid, wherein the particle heavy suspension is Tris-HCl heavy suspension with 100-200mM Tris (containing 250-500mu.g / ml mouse IgG, 1-5% of calf serum, 0.1-0.5% of Pluronic F68, 0.5-1% of casein, 0.9% of NaCl, 0.05% of NaN3) and has a pH being 8-9, the sample pad conditioning fluid contains 10mM PBS (containing 0.1-0.5mg / ml of phytolectin) and has a pH being 7-8. The invention specifically discloses a preparing method of the NT-proBNP fluorescence immunoassay reagent, comprising specific particle marking, sample pad pretreatment, antibody coating on an NC film, and test paper assembling. The NT-proBNP fluorescence immunoassay reagent is high in sensitivity, wide in application range and capable of reducing interference in a serum test, and has a good interception effect on red cells.

The invention discloses an allicin fat emulsion injection and a preparation process thereof; the invention is the drug which is made by the materials with the following mix ratios by weight, while the pH value of which is 6.5 to 7.5, the average particle size of the emulsion particles is 200nm, and the particle size thereof is 100 to 300nm and the Zeta potential is minus 50 to 80mv. The raw materials are: allicin, egg yolk lecithin, pluronic F68, oleic acid, and injection water and so on. The preparation process is that the egg yolk lecithin, oleic acid, vitamin E and soya bean oil are taken at first under the aseptic conditions for mixing, heating, agitating and dissolving, then the allicin is added to agitate till dissolution, and the filtrate can be obtained after the pressure filtration by a microporous membrane; the glycerol is taken at first and the injection water, disodium ethylene diamine tetraacetate and pluronic F68 are added for mixing and agitating till the dissolution, then the filtrate can be obtained after the pressure filtration by the microporous membrane; after the mixture of the two filtrates, a high speed agitator is used for agitating, the product is finally obtained through a high pressure homogenizer. The invention is characterized by no irritating effect and good stability, etc.

The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 μg / mL) and primary bovine primary aortic endothelial cells (IC50>500 μg / mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 μg / mL). Poly(vinyl benzoate) nanoparticles are suitable carriers for molecular delivery of lipophilic small molecules such as drugs pharmaceutical and imaging agents.

The invention discloses a nimodipine oral long-acting suspension and a preparation method thereof. -2 parts, 1-5 parts of pH buffer, 0.1-2 parts of preservative, 90-100 parts of solvent; the carrier material of nimodipine nanoparticles is the composition of polylactic acid-glycolic acid copolymer and pluronic F68, The mass percentage of Pluronic F68 in the carrier material is 5-40%. The nimodipine oral long-acting suspension of the present invention is convenient to take and has a good mouthfeel; the existence of some medicines in a free state can accelerate the absorption rate and have a quick effect; In granules, the first-pass effect can be reduced, the utilization rate of drugs is high, the drug loading capacity of nanoparticles is large, the encapsulation rate is high, the release is slow, and the action time is long, which reduces the frequency of administration and makes up for the shortcomings of existing commercially available dosage forms; preparation The method has good reproducibility and repeatability, and is easy to implement and popularize vigorously in the industry.